GlassScriptPhysician profile
Kwasi Adzotor
NPI 1063631281
$12,211.30
in general payments reported to CMS, 2019-2025
42 companies · $2,680 in 2025
The $2,680 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $110 · 2021: $929 · 2022: $1,929 · 2023: $3,018 · 2024: $1,771 · 2025: $2,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,591 · Travel and Lodging: $1,863 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,591.30 |
| Travel and Lodging | $1,863.21 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,648.44 | 2022-2025 | Visualase, Percept PC Brainsense |
| Alexion Pharmaceuticals, INC. | $1,414.39 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $1,086.12 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $990.96 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $902.00 | 2019-2025 | Vumerity, Spinraza, Tysabri |
| Ucb, INC. | $415.46 | 2019-2025 | Rystiggo, Briviact |
| Amgen INC. | $355.89 | 2019-2021 | |
| Argenx US, INC. | $346.21 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $332.20 | 2022-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $264.73 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $262.87 | 2023-2024 | Austedo Xr, Austedo |
| Abbvie INC. | $259.77 | 2021-2023 | Qulipta |
| Genentech USA, INC. | $256.40 | 2022-2024 | Ocrevus, Enspryng |
| Biohaven Pharmaceutical Holding Company LTD. | $255.75 | 2022 | |
| Horizon Therapeutics Plc | $230.25 | 2022-2023 | Uplizna |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kwasi Adzotor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.